Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the
pancreatic cancer patients treated with adjuvant chemotherapy.
Phase:
Early Phase 1
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborator:
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China